TCTR20211015001
Recruiting
Not Applicable
Rare and childhood cancer multi-omics for precision medicine
Health System Research Institute0 sites1,000 target enrollmentOctober 15, 2021
ConditionsHigh-risk neuroblastoma, refractory or relapsedOsteosarcomaNon-rhabdosarcoma solid tumorsBrain tumors: embryonal tumors &diffused/high grade gliomasAtypical teratoid/rhabdoid tumorNeuroblastomaOsteosarcomaNon-rhabdosarcoma solid tumorsEmbryonal brain tumorsDiffused/high grade gliomasAtypical teratoid/rhabdoid tumor
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- High-risk neuroblastoma, refractory or relapsedOsteosarcomaNon-rhabdosarcoma solid tumorsBrain tumors: embryonal tumors &
- Sponsor
- Health System Research Institute
- Enrollment
- 1000
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age less than 18 years with High\-risk neuroblastoma, refractory or relapsed or Osteosarcoma or Non\-rhabdosarcoma solid tumors or Brain tumors: embryonal tumors \& diffused/high grade gliomas or Atypical teratoid/rhabdoid tumor
Exclusion Criteria
- •1\. No biological parents available
- •2\. Refusal to participate in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesSarcomaEndocrine TumorsNeuroblastomaRetinoblastomaRenal CancerNCT01109394National Cancer Institute (NCI)6,035
Recruiting
Phase 2
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.2024-513779-42-02Oslo University Hospital HF100
Completed
Not Applicable
An integrated multi-omics study of tumor heterogeneity in patients with treatment-resistant malignant cancermalignant cancerJPRN-UMIN000040181Kansai Electric Power Hospital100
Recruiting
Not Applicable
Study on the Diagnostic Value of Multi-omics Combined Detection for Precancerous Lesions of CRCColorectal CancerPrecancerous LesionInflammatory Bowel DiseasesNCT05530746Changhai Hospital500
Recruiting
Phase 2
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelNeoplasmsNCT04449549National Cancer Institute (NCI)82